Siegelin, Markus D.

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy

Strobel, H., Baisch, T., Fitzel, R., Schilberg, K., Siegelin, M. D., Karpel-Massler, G., Debatin, K.-M., & Westhoff, M.-A. (2019) · Biomedicines

Glioma Diagnosis and TreatmentPARP inhibition in cancer therapy

Cited by 279

Insulin-Resistant Brain State after Intracerebroventricular Streptozotocin Injection Exacerbates Alzheimer-like Changes in Tg2576 AβPP-Overexpressing Mice

Plaschke, K., Kopitz, J., Siegelin, M., Schliebs, R., Salkovic-Petrisic, M., Riederer, P., & Hoyer, S. (2010) · Journal of Alzheimer s Disease

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 118

A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3

Halatsch, M.-E., Kast, R. E., Karpel-Massler, G., Mayer, B., Zolk, O., Schmitz, B., Scheuerle, A., Maier, L., Bullinger, L., Mayer-Steinacker, R., et al. (2021) · Neuro-Oncology Advances

Glioma Diagnosis and TreatmentPARP inhibition in cancer therapy

Cited by 74

In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma

Halatsch, M.-E., Dwucet, A., Schmidt, C. J., Mühlnickel, J., Heiland, T., Zeiler, K., Siegelin, M. D., Kast, R. E., & Karpel-Massler, G. (2021) · Pharmaceuticals

Glioma Diagnosis and TreatmentNeuroprotection in Cerebral Ischemia

Cited by 26